Posts Tagged ‘development’

Reduced nephron endowment due to fetal uninephrectomy impairs renal sodium handling in male sheep

January 12th, 2010

Reduced nephron endowment is associated with development of renal and cardiovascular disease. We hypothesised this may be attributable to impaired sodium homeostasis by the remaining nephrons. This study investigated whether a nephron deficit, induced by fetal uninephrectomy at 100d gestation (term=150 days), resulted in 1) altered renal sodium handling both under basal conditions and in response to an acute 0.9% saline load, (50 ml/kg/30minutes); 2) hypertension; and 3) altered expression of renal channels/transporters in male sheep at 6 months of age. Uninephrectomised animals had significantly elevated arterial pressure (90.1±1.6 vs 77.8±2.9; P<0.001) whilst glomerular filtration rate and renal blood flow (per gram of kidney weight) were 30% lower than that of the sham animals. Total kidney weight was similar between the groups. Renal gene expression of apical NHE3, ENaC (β and γ) subunits and basolateral Na+/K+ ATPase (β and γ) subunits were significantly elevated in uninephrectomised animals whilst ENaC α expression was reduced. Urine flow rate and sodium excretion increased in both groups in response to salt loading but this increase in sodium excretion was delayed by approximately 90 min in the uninephrectomised animals, whilst total sodium output was 12% in excess of the infused load (P<0.05). This study shows that animals with a congenital nephron deficit have alterations in tubular sodium channels/transporters and cannot rapidly correct for variations in sodium intake likely contributing to the development of hypertension. This suggests that people born with a nephron deficit should be monitored for early signs of renal and cardiovascular disease.

The rest is here: 
Reduced nephron endowment due to fetal uninephrectomy impairs renal sodium handling in male sheep

Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and…

January 5th, 2010

Recent studies have shown that the renal cytochrome P-450 metabolites of arachidonic acid: the vasoconstrictor 20-hydroxyeicosatetraenoic acid (20-HETE), and the vasodilator epoxyeicosatrienoic acids (EETs) play an important role in the pathophysiology of angiotensin II (ANG II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive Hannover Sprague-Dawley (HanSD) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR rats of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury . This was also associated with an attenuation of the responsiveness of the systemic and renal vascular beds to ANG II without modifying their responses to norepinephrine. Our data suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of ANG II-dependent hypertension. This information provides a basis for a search of new therapeutic approaches to the treatment of hypertension.

Originally posted here:
Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and…

National Science Foundation awards MedChem Partners grant to develop novel chemistry for modification of natural products

December 13th, 2009

MedChem Partners LLC announced today the successful acquisition of a phase I Small Business Innovation Research grant funding from the National Science Foundation to support the development of a broad based chemical technology for the modification of natural products.

Read the original here: 
National Science Foundation awards MedChem Partners grant to develop novel chemistry for modification of natural products

Getting Students Excited About a Life in the Biosciences

November 6th, 2009

This is the VOA Special English Education Report, from voaspecialenglish.com The American biotechnology industry recently did a study of bioscience education across the country. The biosciences are biology and other sciences that deal with living organisms. Paul Hanle is president of the Biotechnology Institute, one of the groups that did the study. He says international tests show that the United States is performing twenty-fifth out of thirty developed countries in science education.So the …

Stem Cells to be a Central Track at GTCbio’s 5th Annual Modern Drug Discovery and Development Conference held on October 14-16, 2009 in San Diego, CA

August 21st, 2009

GTCbio’s 5th Annual Modern Drug Discovery and Development Conference (to be held October 14-16, 2009 in San Diego, CA) has an important focus on Stem Cell Discovery and Development.

Read the rest here: 
Stem Cells to be a Central Track at GTCbio’s 5th Annual Modern Drug Discovery and Development Conference held on October 14-16, 2009 in San Diego, CA